Opinion|Videos|May 29, 2024

Bispecific Antibodies Versus CAR T-Cell Therapy for RRMM in the Community Oncology Setting

Ke Ning, MD, describes similarities and differences when implementing bispecific antibodies and CAR T-cell therapy for patients with relapsed or remitting multiple myeloma in the community oncology setting.

Episodes in this series


Latest CME